Meyers Philip M, Halbach Van V, Dowd Christopher F, Lempert Todd E, Malek Adel M, Phatouros Constantine C, Lefler James E, Higashida Randall T
Department of Radiology, Neurointerventional Division, University of California at San Francisco, USA.
Am J Ophthalmol. 2002 Jul;134(1):85-92. doi: 10.1016/s0002-9394(02)01515-5.
To describe the endovascular treatment and clinical outcome in patients with indirect carotid cavernous fistulas (CCFs) over a 15-year period. To our knowledge, this is the largest series in the medical literature.
Interventional case series.
A retrospective evaluation of 135 consecutive patients who underwent examination and treatment for indirect CCF was performed. Patients received independent evaluations by ophthalmologists, neurologists, or neuro-ophthalmologists before, during, and after endovascular treatment. Patients initially received noninvasive imaging followed by cerebral arteriography for definitive diagnosis and stratification by angiographic risk factors. Endovascular treatment was performed in 133 (98%) patients and clinical follow-up was achieved in 135 (100%) patients on an average of 56 +/- 4.3 months (range: 2 months-14 years). Angiographic follow-up was performed in 72 (54%) patients with ongoing symptoms or a history of fistula with high-risk angiographic features. Arteriographic cure with long-term clinical outcome is summarized by modified Rankin scale (mRS) and Barthel index (BI).
At a mean follow-up of 56 months, 121 (90%) patients were clinically cured. At latest clinical follow-up, 131 (97%) patients showed good recovery (mRS, 1-2; BI 90-100), one (1%) had moderate disability (mRS, 3; BI, 50-60), and three (2%) (mRS, 4; BI, 40-50) were severely disabled. Procedure-related permanent morbidity was 2.3%. There was no operative mortality.
With the observed favorable outcomes and low rate of procedural morbidity in this patient population with long-term angiographic and clinical follow-up, endovascular therapy should be the primary treatment for patients with indirect (dural) fistulas of the cavernous sinus.
描述15年间间接性颈动脉海绵窦瘘(CCF)患者的血管内治疗及临床结果。据我们所知,这是医学文献中最大的系列研究。
介入病例系列研究。
对135例连续接受间接性CCF检查和治疗的患者进行回顾性评估。患者在血管内治疗前、治疗期间及治疗后接受眼科医生、神经科医生或神经眼科医生的独立评估。患者最初接受无创成像检查,随后进行脑血管造影以明确诊断,并根据血管造影危险因素进行分层。133例(98%)患者接受了血管内治疗,135例(100%)患者获得了临床随访,平均随访时间为56±4.3个月(范围:2个月至14年)。72例(54%)有持续症状或有高风险血管造影特征瘘管病史的患者接受了血管造影随访。通过改良Rankin量表(mRS)和Barthel指数(BI)总结血管造影治愈及长期临床结果。
平均随访56个月时,121例(90%)患者临床治愈。在最近的临床随访中,131例(97%)患者恢复良好(mRS,1 - 2;BI 90 - 100),1例(1%)有中度残疾(mRS,3;BI,50 - 60),3例(2%)(mRS,4;BI,40 - 50)严重残疾。与手术相关的永久性发病率为2.3%。无手术死亡病例。
鉴于该患者群体在长期血管造影和临床随访中观察到的良好结果及较低的手术发病率,血管内治疗应作为海绵窦间接(硬脑膜)瘘患者的主要治疗方法。